BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 32859741)

  • 1. Somatic POLE exonuclease domain mutations elicit enhanced intratumoral immune responses in stage II colorectal cancer.
    Mo S; Ma X; Li Y; Zhang L; Hou T; Han-Zhang H; Qian J; Cai S; Huang D; Peng J
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32859741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations in POLE and survival of colorectal cancer patients--link to disease stage and treatment.
    Stenzinger A; Pfarr N; Endris V; Penzel R; Jansen L; Wolf T; Herpel E; Warth A; Klauschen F; Kloor M; Roth W; Bläker H; Chang-Claude J; Brenner H; Hoffmeister M; Weichert W
    Cancer Med; 2014 Dec; 3(6):1527-38. PubMed ID: 25124163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct clinical pattern of colorectal cancer patients with POLE mutations: A retrospective study on real-world data.
    Jiang M; Jia Y; Han J; Shi J; Su C; Zhang R; Xing M; Jin S; Zong H
    Front Genet; 2022; 13():963964. PubMed ID: 36479248
    [No Abstract]   [Full Text] [Related]  

  • 4. Intratumoral infiltrating lymphocytes correlate with improved survival in colorectal cancer patients: Independent of oncogenetic features.
    Nazemalhosseini-Mojarad E; Mohammadpour S; Torshizi Esafahani A; Gharib E; Larki P; Moradi A; Amin Porhoseingholi M; Asadzade Aghdaei H; Kuppen PJK; Zali MR
    J Cell Physiol; 2019 Apr; 234(4):4768-4777. PubMed ID: 30370522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morphological, immunophenotypical and molecular features of hypermutation in colorectal carcinomas with mutations in DNA polymerase ε (POLE).
    Forgó E; Gomez AJ; Steiner D; Zehnder J; Longacre TA
    Histopathology; 2020 Feb; 76(3):366-374. PubMed ID: 31479159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic and transcriptomic characterization of heterogeneous immune subgroups of microsatellite instability-high colorectal cancers.
    Kim JH; Seo MK; Lee JA; Yoo SY; Oh HJ; Kang H; Cho NY; Bae JM; Kang GH; Kim S
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34903553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
    Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
    BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
    Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
    J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct mutational profile and immune microenvironment in microsatellite-unstable and
    Hwang HS; Kim D; Choi J
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34607897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases.
    Buckowitz A; Knaebel HP; Benner A; Bläker H; Gebert J; Kienle P; von Knebel Doeberitz M; Kloor M
    Br J Cancer; 2005 May; 92(9):1746-53. PubMed ID: 15856045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphocytic infiltration in stage II microsatellite stable colorectal tumors: A retrospective prognosis biomarker analysis.
    Sanz-Pamplona R; Melas M; Maoz A; Schmit SL; Rennert H; Lejbkowicz F; Greenson JK; Sanjuan X; Lopez-Zambrano M; Alonso MH; Qu C; McDonnell KJ; Idos GE; Vignali M; Emerson R; Fields P; Guinó E; Santos C; Salazar R; Robins HS; Rennert G; Gruber SB; Moreno V
    PLoS Med; 2020 Sep; 17(9):e1003292. PubMed ID: 32970670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response.
    Temko D; Van Gool IC; Rayner E; Glaire M; Makino S; Brown M; Chegwidden L; Palles C; Depreeuw J; Beggs A; Stathopoulou C; Mason J; Baker AM; Williams M; Cerundolo V; Rei M; Taylor JC; Schuh A; Ahmed A; Amant F; Lambrechts D; Smit VT; Bosse T; Graham TA; Church DN; Tomlinson I
    J Pathol; 2018 Jul; 245(3):283-296. PubMed ID: 29604063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. POLE somatic mutations in advanced colorectal cancer.
    Guerra J; Pinto C; Pinto D; Pinheiro M; Silva R; Peixoto A; Rocha P; Veiga I; Santos C; Santos R; Cabreira V; Lopes P; Henrique R; Teixeira MR
    Cancer Med; 2017 Dec; 6(12):2966-2971. PubMed ID: 29072370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mismatch Repair Status of Gastric Cancer and Its Association with the Local and Systemic Immune Response.
    Shin SJ; Kim SY; Choi YY; Son T; Cheong JH; Hyung WJ; Noh SH; Park CG; Kim HI
    Oncologist; 2019 Sep; 24(9):e835-e844. PubMed ID: 30894409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-Infiltrating Lymphocytes, Tumor Mutational Burden, and Genetic Alterations in Microsatellite Unstable, Microsatellite Stable, or Mutant
    Keshinro A; Vanderbilt C; Kim JK; Firat C; Chen CT; Yaeger R; Ganesh K; Segal NH; Gonen M; Shia J; Stadler Z; Weiser MR
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Importance of lymph node immune responses in MSI-H/dMMR colorectal cancer.
    Inamori K; Togashi Y; Fukuoka S; Akagi K; Ogasawara K; Irie T; Motooka D; Kobayashi Y; Sugiyama D; Kojima M; Shiiya N; Nakamura S; Maruyama S; Suzuki Y; Ito M; Nishikawa H
    JCI Insight; 2021 May; 6(9):. PubMed ID: 33755600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study.
    Domingo E; Freeman-Mills L; Rayner E; Glaire M; Briggs S; Vermeulen L; Fessler E; Medema JP; Boot A; Morreau H; van Wezel T; Liefers GJ; Lothe RA; Danielsen SA; Sveen A; Nesbakken A; Zlobec I; Lugli A; Koelzer VH; Berger MD; Castellví-Bel S; Muñoz J; ; de Bruyn M; Nijman HW; Novelli M; Lawson K; Oukrif D; Frangou E; Dutton P; Tejpar S; Delorenzi M; Kerr R; Kerr D; Tomlinson I; Church DN
    Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):207-216. PubMed ID: 28404093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer.
    van Gool IC; Eggink FA; Freeman-Mills L; Stelloo E; Marchi E; de Bruyn M; Palles C; Nout RA; de Kroon CD; Osse EM; Klenerman P; Creutzberg CL; Tomlinson IP; Smit VT; Nijman HW; Bosse T; Church DN
    Clin Cancer Res; 2015 Jul; 21(14):3347-3355. PubMed ID: 25878334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Association Between Mutations in BRAF and Colorectal Cancer-Specific Survival Depends on Microsatellite Status and Tumor Stage.
    Bläker H; Alwers E; Arnold A; Herpel E; Tagscherer KE; Roth W; Jansen L; Walter V; Kloor M; Chang-Claude J; Brenner H; Hoffmeister M
    Clin Gastroenterol Hepatol; 2019 Feb; 17(3):455-462.e6. PubMed ID: 29660527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathological complete response to immune checkpoint inhibitor in patients with colorectal cancer liver metastases harboring
    Wen L; Chen Z; Ji X; Fong WP; Shao Q; Ren C; Cai Y; Li B; Yuan Y; Wang D; Li Y
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.